Company NovoCure Limited

Equities

NVCR

JE00BYSS4X48

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq Other stock markets 04:00:00 2026-02-10 pm EST			5-day change	1st Jan Change
10.47 ^USD	+4.39%		-11.57%	-19.03%

Jan. 14	NovoCure Limited Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-14-2026 09:45 AM
Jan. 12	NovoCure Reports Rise in Q4 Preliminary Revenue	MT

Business description: NovoCure Limited

NovoCure Limited is a global oncology company. The Company is engaged in the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune and Optune Lua for the treatment of solid tumor cancers. Its commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma, malignant pleural mesothelioma and pleural mesothelioma. It is conducting pivotal studies evaluating the use of TTFields in the treatment of ovarian cancer, brain metastases from non-small cell lung cancer (NSCLC) (brain metastases) and pancreatic cancer. Its key priorities are to drive commercial adoption of Optune, its commercial TTFields device. It also has a license to market Optune in China, Hong Kong, Macau and Taiwan. It has ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer and ovarian cancer.

Number of employees: 1,488

Sales by Activity: NovoCure Limited

Fiscal Period: December	2020 (USD)	2021 (USD)	2022 (USD)	2023 (USD)	2024 (USD)
Tumor Treating Fields (TTFields)	494M	535M	538M	509M	605M

See all business segments

Geographical breakdown of sales: NovoCure Limited

Fiscal Period: December	2020 (USD)	2021 (USD)	2022 (USD)	2023 (USD)	2024 (USD)
United States	341M	353M	407M	350M	392M
Germany	93.26M	93.94M	46.12M	60.21M	65.26M
France	-	-	-	-	55.73M
Other International Markets	-	-	-	44.49M	42.47M
Japan	29.08M	34.64M	32.78M	31.67M	32.57M
Greater China	12.59M	22.76M	21.33M	23.22M	17.39M
Europe, Middle East and Africa (EMEA) (Excluding Germany)	18.65M	30.58M	30.71M	-	-

See all geographic segments

Executive Committee: NovoCure Limited

Manager	Title	Age	Since
Frank Leonard CEO	Chief Executive Officer	46	2025-11-30
Christoph Brackmann DFI	Director of Finance/CFO	52	2024-12-31
Nicolas Leupin CTO	Chief Tech/Sci/R&D Officer	52	2024-01-03
Moshe Giladi CTO	Chief Tech/Sci/R&D Officer	-	2023-01-16
Mukund Paravasthu PRN	Corporate Officer/Principal	-	2019-12-31

See NOVOCURE LIMITED governance

Composition of the Board of Directors: NovoCure Limited

Director	Title	Age	Since
Asaf Danziger BRD	Director/Board Member	58	2011-12-31
Bill Doyle CHM	Chairman	63	2008-12-31
Kin Yip Leung BRD	Director/Board Member	65	2011-08-04
Tony Vernon BRD	Director/Board Member	69	2005-12-31
Martin Madden BRD	Director/Board Member	66	2017-05-09
David Hung BRD	Director/Board Member	69	2018-05-30
Jeryl Hilleman BRD	Director/Board Member	68	2018-07-24
Timothy Scannell BRD	Director/Board Member	61	2021-02-04
Allyson Ocean BRD	Director/Board Member	55	2023-02-22
Kristin Stafford BRD	Director/Board Member	45	2023-03-27

Composition of the Board of Directors

Shareholders: NovoCure Limited

Name	Equities	%	Valuation
Fidelity Management & Research Co. LLC 15.04 %	16,769,878	15.04 %	208 M $
BlackRock Advisors LLC 10.67 %	11,892,851	10.67 %	147 M $
Vanguard Fiduciary Trust Co. 9.829 %	10,958,209	9.829 %	136 M $
Soleus Capital Management LP 8.651 %	9,644,872	8.651 %	120 M $
Hansjörg Wyss 7.303 %	8,141,397	7.303 %	101 M $

List of NOVOCURE LIMITED shareholders

Company details: NovoCure Limited

NovoCure Ltd.

No. 4 The Forum

JE2 4UF, St. Helier

http://www.novocure.com

Medical Equipment

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
NOVOCURE LIMITED	+4.39%	-11.57%	-51.64%	-87.80%	1.17B
PENUMBRA, INC.	-0.02%	-4.78%	+29.85%	+28.12%	13.27B
MASIMO CORPORATION	-0.52%	-3.62%	-24.84%	-18.59%	7.2B
GETINGE AB	+1.57%	+2.74%	-2.46%	-13.82%	6.32B
JIANGSU YUYUE MEDICAL EQUIPMENT & SUPPLY CO., LTD.	-0.40%	+1.10%	+10.62%	+30.23%	5.69B
APT MEDICAL INC.	+5.15%	+6.26%	-3.36%	+43.14%	4.92B
ASAHI INTECC CO., LTD.	+2.19%	+1.60%	+2.21%	+15.63%	4.49B
SHANDONG WEIGAO ORTHOPAEDIC DEVICE CO., LTD	-0.07%	-0.17%	+13.42%	-55.48%	1.71B
IMPLANTICA AG	+2.22%	-6.22%	+9.13%	+16.46%	1.47B
NAKANISHI INC.	-0.04%	+2.17%	-10.28%	-16.57%	1.2B
Average	+1.45%	-1.48%	-2.73%	-5.87%	4.74B
Weighted average by Cap.	+0.99%	-1.22%	+4.62%	+8.69%